

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7023449

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	CORRECTION BY DECLARATION TO NULLIFY 5 ERRONEOUSLY RECORDED PROPERTIES ON COVER SHEET AT REEL 057222 FRAME 0489. ASSIGNOR HEREBY CONFIRMS THE ORIGINAL ASSIGNMENT OF PROPERTIES EXCEPT FOR THOSE LISTED HEREIN FOR NULLIFICATION.	
CONVEYING PARTY DATA		
	Name	Execution Date
	AKORN OPERATING COMPANY LLC	11/12/2021
RECEIVING PARTY DATA		
Name:	AKORN OPERATING COMPANY LLC	
Street Address:	1925 W. FIELD COURT	
City:	LAKE FOREST	
State/Country:	ILLINOIS	
Postal Code:	60045	
PROPERTY NUMBERS Total: 5		
Property Type	Number	
Patent Number:	8759401	
Patent Number:	9517269	
Patent Number:	10426834	
Application Number:	62955249	
Application Number:	62991743	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	steve.trubac@bclplaw.com	
Correspondent Name:	STEVE TRUBAC	
Address Line 1:	161 NORTH CLARK, SUITE 4300	
Address Line 4:	CHICAGO, ILLINOIS 60601	
NAME OF SUBMITTER:	STEVEN G. TRUBAC	
SIGNATURE:	/Steven G. Trubac/	
DATE SIGNED:	11/15/2021	
Total Attachments: 54		

[illegible]

source=AOC Declaration - Patents_111221#page49.tif
source=AOC Declaration - Patents_111221#page50.tif
source=AOC Declaration - Patents_111221#page51.tif
source=AOC Declaration - Patents_111221#page52.tif
source=AOC Declaration - Patents_111221#page53.tif
source=AOC Declaration - Patents_111221#page54.tif

DECLARATION OF REKHA HANU

I, Rekha Hanu, declare:

1. I am a Vice President, Associate General Counsel and Chief IP Counsel for Akorn Operating Company LLC (“AOC”). It is in this capacity in which I make this declaration. I am over the age of 18 and if called as a witness could testify competently and with personal knowledge to the matters set forth herein.

2. AOC as assignor and Medtech Products Inc. (“Medtech”) as assignee executed that certain Assignment of Intellectual Property Rights, dated August 2, 2021, and recorded on August 19, 2021, at Reel/Frame 057222/0489 (“Medtech Assignment”). A true and correct copy of the Medtech Assignment is attached hereto as Exhibit 1.

3. The patent assignment schedule to the Medtech Assignment (Exhibit A to the Medtech Assignment) identified the ten (10) patent properties assigned to Medtech. The properties assigned from AOC to Medtech and properly recorded at Reel/Frame 057222/0489 are as follows:

<u>Title</u>	<u>App. No.</u>	<u>Reg. No.</u>	<u>Reg. Date</u>	<u>Current Owner</u>
Cleanser Compositions and Methods for Using the Same	16997148	N/A	N/A	Medtech Products, Inc.
Cleanser Compositions and Methods for Using the Same	17211952	N/A	N/A	Medtech Products, Inc.
Cleanser Composition and Methods for Using the Same	12771246	8231912	07-31-12	Medtech Products, Inc.
Cleanser Compositions and Methods for Using the Same	14722252	N/A	N/A	Medtech Products, Inc.
Cleanser Compositions and Methods for Using the Same	13539531	8449928	05-28-13	Medtech Products, Inc.
Cleanser Compositions	13871133	8932653	01-13-15	Medtech Products,

<u>Title</u>	<u>App. No.</u>	<u>Reg. No.</u>	<u>Reg. Date</u>	<u>Current Owner</u>
and Methods for Using the Same				Inc.
Cleanser Compositions and Methods for Using the Same	14528420	9050288	06-09-15	Medtech Products, Inc.
Method of Treatment Using a Therapeutic Agent for Intranasal Administration	14082890	8900643	12-02-14	Medtech Products, Inc.
Method of Treatment Using a Therapeutic Agent for Intranasal Administration	14464177	9301988	04-05-16	Medtech Products, Inc.
Methods and Compositions for the Treatment of Infection or Infectious Colonization of the Eyelid, Ocular Surface, Skin or Ear	13523512	8535736	09-17-13	Medtech Products, Inc.

5. In addition to the above assigned and properly recorded properties, the patent assignment cover sheet to the Medtech Assignment (attached hereto as Exhibit 2) erroneously included the five (5) patent applications and registrations in the chart below that were not listed in the assignment schedule to the Medtech Assignment, and were not assigned to Medtech (these 5 properties are hereinafter referred to as the “AOC Patents”). As shown in the recorded chain of title for the AOC Patents, the last actual assignments of the AOC Patents are recorded at Reel/Frame 055326/0694, which confirms AOC as the current assignee and owner of the AOC Patents.

6. Each of the below applications and registrations belong to AOC and not to Medtech – indeed they were never assigned to Medtech. As such, AOC hereby requests that the USPTO correct the improper recordation made at Reel/Frame 057222/0489 by nullifying the recordation with respect to the AOC Patents, namely, the following U.S. patent applications and

registrations:

<u>Title</u>	<u>App. No.</u>	<u>Reg. No.</u>	<u>Reg. Date</u>	<u>Current Owner</u>
Aqueous Gel Formulation and Method for Inducing Topical Anesthesia	13961453	8759401	06-24-14	Akorn Operating Company LLC
Stable Pentobarbital Formulation	14617404	9517269	12-13-16	Akorn Operating Company LLC
Methods of Sterilizing Drugs	15674791	10426834	10-01-19	Akorn Operating Company LLC
Ready to Use Ephedrine Formulation and its Uses Thereof	62955249	N/A	N/A	Akorn Operating Company LLC
Ophthalmic Suspension Compositions and Process for the Preparation of Same	62991743	N/A	N/A	Akorn Operating Company LLC

7. AOC, as the last correct owner and assignee, has been and continues to be the owner of the AOC Patents shown in the listing above.

I declare under penalty of perjury, pursuant to 28 U.S.C. § 1746(2), that the foregoing is true and correct to the best of my knowledge.

Date: November 12, 2021

DocuSigned by:

Rekha Hanu

61CDD39C1A04113D
Rekha Hanu

EXHIBIT 1

Assignment of Intellectual Property Rights

WHEREAS, Akorn Operating Company LLC, a Delaware limited liability company ("Seller"), and Medtech Products Inc., a Delaware corporation ("Buyer"), are parties to that certain Asset Purchase Agreement dated as of May 27, 2021 (the "Asset Purchase Agreement");

WHEREAS, Seller confirms that certain intellectual property listed in Exhibit A which is registered in the name of Advanced Vision Research, Inc. was assigned to Seller pursuant to that certain Patent Assignment Agreement between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co, LLC, on the one hand, and Seller, on the other hand, dated October 1, 2020 and that certain Trademark Assignment Agreement between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co, LLC, on the one hand, and Seller, on the other hand dated October 1, 2020, both of which are attached as Exhibit B; and

WHEREAS, pursuant to the Asset Purchase Agreement, Seller is assigning and transferring the Transferred Owned Intellectual Property Rights (as such term is defined in the Asset Purchase Agreement) to Buyer;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Seller hereby assigns, grants, transfers and conveys (and agrees to assign, grant, transfer and convey) to Buyer, its successors and assigns all of its right, title and interest throughout the world in and to the Transferred Owned Intellectual Property Rights (including, as applicable, all copyrights, patents, trademarks, trade secrets and other intellectual property rights and all of its other rights in the Transferred Owned Intellectual Property Rights that may now or hereafter be vested) including the intellectual property listed in Exhibit A, together with all national, foreign, state and common law registrations, applications for registration and renewals and extensions thereof; all goodwill associated therewith; and all benefits, privileges, causes of action and remedies relating to any of the foregoing hereafter accrued (including, without limitation, the rights to apply for and maintain all such registrations, renewals and/or extensions; to sue for infringements or other violations of its rights in the Transferred Owned Intellectual Property Rights; and to settle and retain proceeds from any such actions).

Seller also agrees to execute such written instruments, extend such other cooperation and perform such other acts as may be necessary, in the reasonable opinion of Buyer, to register a copyright or trademark, obtain a patent or otherwise enforce Buyer's rights in the Transferred Owned Intellectual Property Rights all of the foregoing at Buyer's sole cost and expense; and Seller hereby irrevocably appoint Buyer and any of its officers as Seller's attorney in fact to undertake such acts in Seller's name.


This assignment agreement, together with the Asset Purchase Agreement and the other Ancillary Agreements (as such term is defined in the Asset Purchase Agreement) constitute the entire agreement between Seller and Buyer concerning the subject matter hereof and supersedes all prior or contemporaneous discussions, communications and agreements, whether oral or written, between Seller and Buyer relating to the subject matter hereof.

[Signature page follows]

IN WITNESS WHEREOF, Buyer and Seller have caused this Assignment Agreement to be duly executed as of August 2, 2021 by their respective officers thereunto duly authorized.

BUYER:

MEDTECH PRODUCTS INC.

By: 

Name: Christine Sacco

Title: Chief Financial Officer

[Signature Page to Assignment of Intellectual Property Rights]

PATENT
REEL: 058107 FRAME: 0608

SELLER:

AKORN OPERATING COMPANY LLC

By:

Name: Douglas S. Boothe

Title: President and CEO

[Signature Page to Assignment of Intellectual Property Rights]

PATENT
REEL: 058107 FRAME: 0609

Exhibit A

Trademarks

#	Title	Jurisdiction	App. No.	App. Date	Reg. No.	Reg. Date	Owner
1.	DESIGN ONLY	USA	88/581,415	8/16/2019	N/A	N/A	Akorn Operating Company LLC
2.	RESTORES EYES NATURAL BALANCE CLEANSES EYELIDS AND LASHES NOURISHES EYES TO PROMOTE HEALTHY TEARS and Design	USA	88/070,824	8/9/2018	N/A	N/A	Akorn Operating Company LLC
3.	STERILID	New Zealand	1131346	10/1/2019	N/A	N/A	Akorn Operating Company LLC
4.	THERAREARS EXTRA	USA	88/047,652	7/23/2018	N/A	N/A	Akorn Operating Company LLC
5.	RESTORES + CLEANSES +NOURISHES and Design	USA	88/072,677	8/9/2018	N/A	N/A	Akorn Operating Company LLC
6.	HYDROLOCK	USA	90/552,357	3/1/2021	N/A	N/A	Akorn Operating Company LLC
7.	DESIGN ONLY	USA	88/581,415	8/16/2019	N/A	N/A	Akorn Operating Company LLC
8.	DIABETIC TUSSIN	USA	74389373	5/4/1993	1,861,344	11/1/1994	Akorn Operating Company LLC
9.	FAST AND FIERCE RELIEF	USA	87007235	4/20/2016	5,355,854	12/12/2017	Akorn Operating Company LLC
10.	HEADACHE BUSTER	Canada	1449250	8/24/2009	TMA787365	1/14/2011	Akorn Operating Company LLC
11.	JEFFREY P. GILBARD, MD	USA	85121025	9/1/2010	4,556,180	6/24/2014	Akorn Operating Company LLC
12.	MAGINEX	Canada	1083318	11/20/2000	TMA641833	6/13/2005	Akorn Operating Company LLC

#	Title	Jurisdiction	App. No.	App. Date	Reg. No.	Reg. Date	Owner
13.	MAGINEX	USA	76052135	5/19/2000	2,541,622	2/19/2002	Akorn Operating Company LLC
14.	MAG-OX 400	USA	75576028	10/23/1998	2,633,768	10/15/2002	Akorn Operating Company LLC
15.	MASTER OF MAGNESIUM	USA	87007233	4/20/2016	5,355,853	12/12/2017	Akorn Operating Company LLC
16.	MULTI-BETIC	USA	86210334	3/4/2014	4,613,666	9/30/1994	Akorn Operating Company LLC
17.	OSMO-CORRECTION	USA	85967253	6/22/2013	4,837,201	10/20/2015	Akorn Operating Company LLC
18.	PHARMACEUTICAL GRADE (& design)	USA	78329276	11/18/2003	3,272,765	7/31/2007	Akorn Operating Company LLC
19.	RESTORES EYES NATURAL BALANCE	USA	85967251	6/22/2013	4,846,473	11/3/2015	Akorn Operating Company LLC
20.	SINUS BUSTER	Canada	1378181	1/7/2008	TMA733034	1/22/2009	Akorn Operating Company LLC
21.	SINUS BUSTER	USA	78862364	4/16/2006	3,194,160	1/2/2007	Akorn Operating Company LLC
22.	SINUS BUSTER ALL NATURAL NASAL SPRAY	USA	78850704	3/30/2006	3,503,088	9/16/2008	Akorn Operating Company LLC
23.	SINUS GENIE	Canada	1378171	1/7/2008	TMA732672	1/19/2009	Akorn Operating Company LLC
24.	STERILID	Australia	1064550	7/12/2005	1064550	7/12/2005	Akorn Operating Company LLC
25.	STERILID	EU	4549721	7/14/2005	4549721	6/14/2006	Akorn Operating Company LLC
26.	STERILID	India	1376561	8/8/2005	1376561	8/8/2005	Akorn Operating Company LLC
27.	STERILID	Mexico	731418	7/29/2005	907,931	11/16/2005	Akorn Operating Company LLC
28.	STERILID	New Zealand	1131346	10/1/2019	1131346	2/2/2021	Akorn Operating Company LLC
29.	STERILID	UK	UK009045497 21	7/14/2005	UK009045497 21	6/14/2006	Akorn Operating Company LLC

#	Title	Jurisdiction	App. No.	App. Date	Reg. No.	Reg. Date	Owner
30.	STERILID	USA	78459733	7/30/2004	3,140,041	9/5/2006	Akorn Operating Company LLC
31.	THERA LID	Canada	1387723	3/17/2008	TMA766079	5/7/2010	Akorn Operating Company LLC
32.	THERA TEARS	EU	2996155	1/3/2003	2996155	10/14/2004	Akorn Operating Company LLC
33.	THERA TEARS	Mexico	731417	7/29/2005	902036	9/28/2005	Akorn Operating Company LLC
34.	THERA TEARS	USA	88457133	6/3/2019	5,943,133	12/24/2019	Akorn Operating Company LLC
35.	THERA TEARS STERILID	USA	78459728	7/30/2004	3,181,614	12/5/2006	Akorn Operating Company LLC
36.	THERA TEARS	USA	74615598	12/27/1994	2,041,112	10/27/1997	Akorn Operating Company LLC
37.	THERAPY FOR YOUR EYES	USA	86260607	4/23/2014	4,843,058	10/27/2015	Akorn Operating Company LLC
38.	THERATEARS EXTRA	USA	87049747	5/25/2016	5,586,699	10/16/2018	Akorn Operating Company LLC
39.	THERATEARS	Australia	7301 82	3/18/1997	7301 82	3/18/1997	Akorn Operating Company LLC
40.	THERATEARS	Canada	1085366	12/4/2000	TMA573256	1/8/2003	Akorn Operating Company LLC
41.	THERATEARS	Canada	1153395	9/23/2002	TMA641310	6/3/2005	Akorn Operating Company LLC
42.	THERATEARS	EU	2153476	3/22/2001	2153476	7/16/2002	Akorn Operating Company LLC
43.	THERATEARS	Guatemala	2014000962	2/4/2014	201476	11/13/2014	Akorn Operating Company LLC
44.	THERATEARS	India	1376560	8/8/2005	1376560	8/8/2005	Akorn Operating Company LLC
45.	THERATEARS	International Register	1197342	1/21/2014	1197342	1/21/2014	Akorn Operating Company LLC
46.	THERATEARS	Lebanon	N/A	N/A	155229	2/5/2014	Akorn Operating Company LLC

#	Title	Jurisdiction	App. No.	App. Date	Reg. No.	Reg. Date	Owner
47.	THERATEARS	New Zealand	274324	3/19/1997	274324	10/17/1997	Akorn Operating Company LLC
48.	THERATEARS	Norway (IR)	1197342	1/21/2014	1197342	1/21/2014	Akorn Operating Company LLC
49.	THERATEARS	South Africa	2014/01774	1/24/2014	2014/01774	7/30/2015	Akorn Operating Company LLC
50.	THERATEARS	UK	UK00902153476	3/22/2001	UK00902153476	EXPIRED	Akorn Operating Company LLC
51.	THERATEARS	Singapore (IR)	1197342	1/21/2014	1197342	1/21/2014	Akorn Operating Company LLC
52.	THERATEARS	Switzerland (IR)	1197342	1/21/2014	1197342	1/21/2014	Akorn Operating Company LLC
53.	THERATEARS	USA	76427523	7/5/2002	2,770,188	9/30/2003	Akorn Operating Company LLC
54.	THERATEARS STERILID	USA	78459728	7/30/2004	3,181,614	12/5/2006	Akorn Operating Company LLC
55.	TYPE YOU	Canada	1728450	5/15/2015	TMA1040395	7/11/2019	Akorn Operating Company LLC
56.	TYPE YOU	USA	86631044	5/15/2015	5,291,486	9/19/2017	Akorn Operating Company LLC
57.	TYPE YOU DIABETIC CARE	Canada	1776093	4/7/2016	TMA1047727	8/8/2019	Akorn Operating Company LLC
58.	TYPE YOU DIABETIC CARE	USA	86966811	4/6/2016	5,297,364	9/26/2017	Akorn Operating Company LLC
59.	ZOSTRIX	USA	78660833	6/29/2005	3,106,587	6/20/2006	Akorn Operating Company LLC
60.	ZOSTRIX	USA	73576274	1/6/1986	1,423,561	1/6/1987	Akorn Operating Company LLC
61.	THERATEARS	Kuwait	N/A	N/A	130439	2/17/2014	Akorn Operating Company LLC
62.	URO-MAG	USA	72450878	3/8/1973	974841	12/18/1973	Akorn Operating Company LLC

Patents

#	Title	Jurisdiction	App. No.	App. Date	Reg. No.	Reg. Date	Owner
1.	Cleanser compositions and methods for using the same	U.S.	16/997,148	8/19/2020	N/A	N/A	Akorn Operating Company LLC
2.	Cleanser compositions and methods for using the same	U.S.	17/211,952	3/25/2021	N/A	N/A	Akorn Operating Company LLC
3.	Cleanser composition and methods for using the same	U.S.	12/771,246	4/30/2010	8231912	7/31/2012	Akorn Operating Company LLC
4.	Cleanser composition and methods for using the same	U.S.	14/722,252	5/27/2015	ABANDONED	ABANDONED	Akorn Operating Company LLC
5.	Cleanser Compositions And Methods For Using The Same	Australia	2010242866	4/30/2010	2010242866	4/30/2010	Akorn Operating Company LLC
6.	Cleanser Compositions And Methods For Using The Same	Austria	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
7.	Cleanser Compositions And Methods For Using The Same	Bulgaria	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
8.	Cleanser Compositions And Methods For Using The Same	Canada	CA2760591	4/30/2010	CA2760591	1/2/2018	Akorn Operating Company LLC
9.	Cleanser Compositions And Methods For Using The Same	Cyprus	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
10.	Cleanser Compositions And Methods For Using The Same	Denmark	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
11.	Cleanser Compositions And Methods For Using The Same	Estonia	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
12.	Cleanser Compositions And Methods For Using The Same	European	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
13.	Cleanser Compositions And Methods For Using The Same	Finland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating

							Company LLC
14.	Cleanser Compositions And Methods For Using The Same	France	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
15.	Cleanser Compositions And Methods For Using The Same	Germany	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
16.	Cleanser Compositions And Methods For Using The Same	Greece	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
17.	Cleanser Compositions And Methods For Using The Same	Iceland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
18.	Cleanser Compositions And Methods For Using The Same	Ireland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
19.	Cleanser Compositions And Methods For Using The Same	Italy	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
20.	Cleanser Compositions And Methods For Using The Same	Latvia	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
21.	Cleanser Compositions And Methods For Using The Same	Lithuania	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
22.	Cleanser Compositions And Methods For Using The Same	Netherlands	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
23.	Cleanser Compositions And Methods For Using The Same	New Zealand	596254	11/7/2011	596254	10/1/2013	Akorn Operating Company LLC
24.	Cleanser Compositions And Methods For Using The Same	Norway	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
25.	Cleanser Compositions And Methods For Using The Same	Poland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
26.	Cleanser Compositions And Methods For Using The Same	Portugal	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC

27.	Cleanser Compositions And Methods For Using The Same	Romania	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
28.	Cleanser Compositions And Methods For Using The Same	Spain	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
29.	Cleanser Compositions And Methods For Using The Same	Sweden	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
30.	Cleanser Compositions And Methods For Using The Same	Switzerland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
31.	Cleanser compositions and methods for using the same	U.S.	13/539,531	7/2/2012	8449928	5/28/2013	Akorn Operating Company LLC
32.	Cleanser compositions and methods for using the same	U.S.	13/871,133	4/26/2013	8932653	1/13/2015	Akorn Operating Company LLC
33.	Cleanser compositions and methods for using the same	U.S.	14/528,420	10/30/2014	9050288	6/9/2015	Akorn Operating Company LLC
34.	Cleanser Compositions And Methods For Using The Same	United Kingdom	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
35.	Method of treatment using a therapeutic agent for intranasal administration	U.S.	14/082,890	11/18/2013	8900643	12/2/2014	Akorn Operating Company LLC
36.	Method of treatment using a therapeutic agent for intranasal administration	U.S.	14/464,177	8/20/2014	9301988	4/5/2016	Akorn Operating Company LLC
37.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Australia	2007238666	4/12/2007	2007238666	8/22/2013	Akorn Operating Company LLC
38.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Austria	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

39.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Canada	2650136	4/12/2007	2650136	7/7/2015	Akorn Operating Company LLC
40.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Denmark	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
41.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Estonia	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
42.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	European	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
43.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Finland	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
44.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	France	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
45.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Germany	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
46.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The	Greece	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

	Eyelid, Ocular Surface, Skin Or Ear						
47.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Italy	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
48.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Liechtenstein	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
49.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	New Zealand	571810	10/7/2008	571810	10/8/2012	Akorn Operating Company LLC
50.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Spain	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
51.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Sweden	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
52.	Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Switzerland	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
53.	Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear	U.S.	13/523,512	6/14/2012	8535736	9/17/2013	Akorn Operating Company LLC
54.	Methods And Compositions For The Treatment Of Infection Or Infectious	United Kingdom	7755402	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

	Colonization Of The Eyelid, Ocular Surface, Skin Or Ear						
--	---	--	--	--	--	--	--

Exhibit B

[See attached]

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6373911

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AKORN, INC.	10/01/2020
ADVANCED VISION RESEARCH, LLC	10/01/2020
HI-TECH PHARMACAL CO., LLC	10/01/2020
RECEIVING PARTY DATA	
Name:	AKORN OPERATING COMPANY, LLC
Street Address:	1925 W. FIELD COURT
City:	LAKE FOREST
State/Country:	ILLINOIS
Postal Code:	60045
PROPERTY NUMBERS Total: 13	
Property Type	Number
Application Number:	14722252
Application Number:	62955249
Application Number:	62991743
Application Number:	13961453
Application Number:	12771246
Application Number:	13539531
Application Number:	13871133
Application Number:	14528420
Application Number:	14082890
Application Number:	14464177
Application Number:	13523512
Application Number:	15674791
Application Number:	14617404
CORRESPONDENCE DATA	
Fax Number:	(312)862-2200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3128622000

Email: rob.soneson@kirkland.com
Correspondent Name: ROB SONESON
Address Line 1: 300 N LASALLE
Address Line 2: KIRKLAND & ELLIS LLP
Address Line 4: CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 14581-66-RFS

NAME OF SUBMITTER: ROB SONESON

SIGNATURE: /rsoneson/

DATE SIGNED: 10/28/2020

Total Attachments: 14

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page1.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page2.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page3.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page4.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page5.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page6.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page7.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page8.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page9.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page10.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page11.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page12.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page13.tif

source=Exhibit B_ Omnibus Patent Assignment Agreement - Project Wood (K&E draft 9-28-20)_(72078373_1)#page14.tif

PATENT ASSIGNMENT AGREEMENT

This PATENT ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”) and is by and between Akorn, Inc., Advanced Vision Research, LLC, and Hi-Tech Pharmacal Co., LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the patents and patent applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Patents**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which APA Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Assigned Patents which are part of the Acquired Assets; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(b) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. **Assignment.** Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s right, title, and interest throughout the world in and to the Assigned Patents, including any continuation, continuation-in-part, divisional, extension, substitution, re-examination, or reissue thereof or any legal equivalent in the United States or a foreign country for the full term or terms for which the same may be granted, including the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties,

damages, and payments hereafter due or payable with respect to the Assigned Patents (except to the extent arising under prior patent license agreements included in the Excluded Contracts), the right to prosecute, maintain and defend the Assigned Patents before any public or private agency, office or registrar, and all claims, causes of action and rights to sue for past, present and future infringement or unconsented use of the Assigned Patents. Each Assignor authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Patents and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Patents in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Patents with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Patents with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement (including the Schedules and exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of the Purchase Agreement and this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.


7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:


AKORN, INC.

By: 
Name: Joseph Bonaccorsi
Title: Executive Vice President, General Counsel, and Secretary

ADVANCED VISION RESEARCH, LLC

By: 
Name: Joseph Bonaccorsi
Title: Authorized Signatory


HI-TECH PHARMACAL CO., LLC

By: 
Name: Joseph Bonaccorsi
Title: Authorized Signatory

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel, and Secretary

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

PATENT
REEL: 058107 FRAME: 0627

EXHIBIT A**Patent Applications**

Title	Jurisdiction	Application No.	Filing Date	Status	Current Owner of Record
Cleanser compositions and methods for using the same	U.S.	14/722,252	5/27/2015	Pending	Akorn Operating Company LLC
Ready to use ephedrine formulation and its uses thereof	U.S.	62/955,249	12/30/2019	Pending	Akorn Operating Company LLC
Ophthalmic Suspension Compositions and Process for the Preparation of Same	U.S.	62/991,743	3/19/2020	Pending	Akorn Operating Company LLC

Patents

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Aqueous gel formulation and method for inducing topical anesthesia	U.S.	13/961,453	8/7/2013	8759401	6/24/2014	Akorn Operating Company LLC
Cleanser composition and methods for using the same	U.S.	12/771,246	4/30/2010	8231912	7/31/2012	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Cleanser Compositions And Methods For Using The Same	Australia	2010242866	4/30/2010	2010242866	4/30/2010	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Austria	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Bulgaria	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Cyprus	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Denmark	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Estonia	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	European	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Cleanser Compositions And Methods For Using The Same	Finland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	France	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Germany	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Greece	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Iceland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Ireland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Italy	502018000011485 (10770410.8)	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Cleanser Compositions And Methods For Using The Same	Latvia	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Lithuania	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Netherlands	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	New Zealand	596254	11/7/2011	596254	10/1/2013	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Norway	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Poland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Portugal	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Cleanser Compositions And Methods For Using The Same	Romania	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Spain	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Sweden	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser Compositions And Methods For Using The Same	Switzerland	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Cleanser compositions and methods for using the same	U.S.	13/539,531	7/2/2012	8449928	5/28/2013	Akorn Operating Company LLC
Cleanser compositions and methods for using the same	U.S.	13/871,133	4/26/2013	8932653	1/13/2015	Akorn Operating Company LLC
Cleanser compositions and methods for using the same	U.S.	14/528,420	10/30/2014	9050288	6/9/2015	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Cleanser Compositions And Methods For Using The Same	United Kingdom	10770410.8	4/30/2010	2424374	1/17/2018	Akorn Operating Company LLC
Method of treatment using a therapeutic agent for intranasal administration	U.S.	14/082,890	11/18/2013	8900643	12/2/2014	Akorn Operating Company LLC
Method of treatment using a therapeutic agent for intranasal administration	U.S.	14/464,177	8/20/2014	9301988	4/5/2016	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Australia	2007238666	4/12/2007	2007238666	08/22/2013	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Austria	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Canada	2650136	4/12/2007	2650136	7/7/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Denmark	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Estonia	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	European	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Finland	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	France	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Germany	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Greece	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Italy	502015000064091 (07755402.0)	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Liechtenstein	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	New Zealand	571810	10/7/2008	571810	10/8/2012	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Spain	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Sweden	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	Switzerland	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC
Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear	U.S.	13/523,512	6/14/2012	8535736	9/17/2013	Akorn Operating Company LLC
Methods And Compositions For The Treatment Of Infection Or Infectious Colonization Of The Eyelid, Ocular Surface, Skin Or Ear	United Kingdom	07755402.0	4/12/2007	2018103	8/26/2015	Akorn Operating Company LLC

Title	Jurisdiction	Application No.	Filing Date	Patent No.	Registration Date	Current Owner of Record
Methods of sterilizing drugs	U.S.	15/674,791	8/11/2017	10426834	10/1/2019	Akorn Operating Company LLC
Stable pentobarbital formulation	U.S.	14/617,404	2/9/2015	9517269	12/13/2016	Akorn Operating Company LLC

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM610993

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Advanced Vision Research, LLC		10/01/2020	Limited Liability Company: DELAWARE
Hi-Tech Pharmacal Co., LLC		10/01/2020	Limited Liability Company: DELAWARE
Akorn Animal Health, LLC		10/01/2020	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Akorn Operating Company LLC		
Street Address:	1925 W. Field Court		
City:	Lake Forest		
State/Country:	ILLINOIS		
Postal Code:	60045		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	88581415		
Serial Number:	88677127	DETOMISED	
Serial Number:	88164134	MACUTRITION	
Serial Number:	88677131	PROPOSED	
Serial Number:	88072677	RESTORES + CLEANSSES + NOURISHES	
Serial Number:	88070824	RESTORES EYES NATURAL BALANCE CLEANSSES E	
Serial Number:	87413349	STERI-OPTICS	
Serial Number:	88047652	THERATEARS EXTRA	
CORRESPONDENCE DATA			
Fax Number:	3128622200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	3128622000		
Email:	rob.soneson@kirkland.com		
Correspondent Name:	ROB SONESON		
Address Line 1:	300 N LASALLE		

CH \$215.00 88581415

Address Line 2:	KIRKLAND & ELLIS LLP
Address Line 4:	CHICAGO, ILLINOIS 60654

ATTORNEY DOCKET NUMBER:	14581-66-RFS
--------------------------------	--------------

NAME OF SUBMITTER:	Rob Soneson
---------------------------	-------------

SIGNATURE:	/rsoneson/
-------------------	------------

DATE SIGNED:	11/25/2020
---------------------	------------

Total Attachments: 14

source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page1.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page2.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page3.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page4.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page5.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page6.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page7.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page8.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page9.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page10.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page11.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page12.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page13.tif
source=Exhibit C - Trademark Assignment Agreement 11.25.2020 ITU Filing Copy#page14.tif

TRADEMARK ASSIGNMENT AGREEMENT

This TRADEMARK ASSIGNMENT AGREEMENT is dated as of October 1, 2020 (this “**Assignment**”), and is by and between Akorn, Inc., Advanced Vision Research, LLC, Hi-Tech Pharmacal Co., LLC, Akorn Animal Health, LLC, Clover Pharmaceuticals LLC, Akorn International S.À.R.L., Oak Pharmaceuticals, LLC., Inspire Pharmaceuticals, LLC, and VersaPharm LLC (each, an “**Assignor**” and collectively, the “**Assignors**”) on the one hand, and Akorn Operating Company LLC (“**Assignee**”) on the other hand. Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

WHEREAS, Assignors are the owners of the trademark registrations and applications for which it is listed as the current owner of record on **Exhibit A** (collectively, the “**Assigned Trademarks**”);

WHEREAS, Assignors and Akorn Holdings Topco LLC (“**APA Purchaser**”) are parties to that certain Asset Purchase Agreement, dated as of May 20, 2020 (the “**Purchase Agreement**”), pursuant to which Purchaser agreed to purchase the Acquired Assets and agreed to assume the Assumed Liabilities from Sellers;

WHEREAS Assignors, Assignee, APA Purchaser, and certain other parties set forth on the signature pages thereto entered into that certain Implementation Agreement, dated as of the date hereof (the “**Implementation Agreement**”), providing for, among other things, (i) a G Reorganization Election and (ii) in order to implement the G Reorganization, an agreement among the parties thereto that, notwithstanding the provisions of the Purchase Agreement, on the date hereof (a) the Sellers will transfer, assign, convey, and deliver to Assignee all of the Sellers’ right, title and interest in the Acquired Assets, free and clear of all Encumbrances other than Permitted Encumbrances and (b) Assignee will assume from Sellers the Assumed Liabilities;

WHEREAS, in order to effectuate the transactions contemplated by the Purchase Agreement, as amended by the Implementation Agreement, and pursuant to the terms and conditions thereof, Assignors and Assignee are hereby effecting the sale, conveyance, assignment, and transfer of all of the Acquired Assets, which assets include the Assigned Trademarks; and

WHEREAS, this Assignment is being executed and delivered pursuant to Section 2.3(c) of the Purchase Agreement.

NOW, THEREFORE, in accordance with the Purchase Agreement, as amended by the Implementation Agreement, and in consideration of the premises and the mutual agreements and covenants set forth in this Assignment, the Purchase Agreement and the Implementation Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the parties hereby agree as follows:

1. **Assignment**. Each of the Assignors, subject to any encumbrances related to prior agreements, hereby irrevocably sells, conveys, transfers, assigns, and delivers to Assignee all of each Assignor’s worldwide right, title, and interest throughout the world in and to the Assigned Trademarks, together with that portion of such Assignor’s business connected with the use of and

symbolized by the Assigned Trademarks, and all past and present goodwill associated therewith or symbolized thereby, all common law rights thereto, all registrations that have been or may be granted thereon, all applications for registrations thereof, the right to claim priority in accordance with international treaties and conventions, the right to all income, royalties, damages, and payments hereafter due or payable with respect to the Assigned Trademarks, the right to register, prosecute, maintain, and defend the Assigned Trademarks before any public or private agency, office, or registrar, and all claims, causes of action, and rights to sue for past, present, and future infringement or unconsented use of the Assigned Trademarks. Each of the Assignors authorizes the Commissioner of Patents and Trademarks in the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign countries or multinational authorities, to record Assignee as the assignee of all of each Assignor's right, title, and interest in and to the Assigned Trademarks and to deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications.

2. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned Trademarks in Assignee, its successors, and assigns, at Assignee's sole cost and expense. If the Assignee is unable, after reasonable effort, to secure the Assignor's signature on any such documentation for any reason whatsoever, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents as such Assignor's agent and attorney-in-fact, to act for and in such Assignor's behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to further the prosecution, issuance, and perfection of the Assigned Trademarks with the same legal force and effect as if executed by such Assignor. For the avoidance of doubt, all fees incurred in connection with any filings relating to the assignment of the Assigned Trademarks with the United States Patent and Trademark Office or any foreign equivalent thereof will be paid by Assignee.

3. No Third Party Beneficiaries. This Assignment is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein expressed or implied shall give or be construed to give to any person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.

4. Terms of Purchase Agreement; Conflicts. The scope, nature, and extent of the Acquired Assets are expressly set forth in the Purchase Agreement. Nothing contained herein changes, amends, modifies, extends, limits, or otherwise alters (nor shall this Assignment be deemed or construed as changing, amending, modifying, extending, limiting or altering) the terms or conditions of the Purchase Agreement, as amended by the Implementation Agreement, in any manner whatsoever. This instrument does not create or establish rights, liabilities, or obligations not otherwise created or existing under or pursuant to the Purchase Agreement, as amended by the Implementation Agreement. The parties hereto acknowledge and agree that the representations, warranties, covenants, agreements, and indemnities contained in the Purchase Agreement, as amended by the Implementation Agreement, will not be superseded hereby but will remain in full force and effect to the full extent provided therein. In the event of any conflict between the provisions of this Assignment (including the exhibits) and the provisions of the Purchase Agreement, as amended by the Implementation Agreement, (including the Schedules and

exhibits), the provisions of the Purchase Agreement, as amended by the Implementation Agreement, shall govern, supersede and control in all respects to the extent of such conflict.

5. Governing Law. This Assignment, the negotiation, execution or performance of this Assignment and any disputes arising under or related hereto (whether for breach of contract, tortious conduct, or otherwise) shall be governed and construed in accordance with the Laws of the State of Delaware, without reference to its conflicts of law principles.

6. Entire Agreement. This Assignment, and the exhibits annexed hereto, and the Purchase Agreement, as amended by the Implementation Agreement, and the other agreements, certificates, and other documents contemplated hereby and thereby constitute the entire understanding among the parties hereto with respect to the subject matter hereof and thereof, and supersede all other understandings and negotiations with respect thereto. The parties hereto agree to define their rights, liabilities, and obligations with respect to such understanding and the transactions contemplated hereby exclusively in contract pursuant to the express terms and provisions of this Assignment, and the parties hereto expressly disclaim that they are owed any duties or are entitled to any remedies not expressly set forth in this Assignment or the Purchase Agreement, as amended by the Implementation Agreement.

7. Counterparts. This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same agreement, and shall become effective when each party hereto shall have received counterparts hereof signed by each of the other parties hereto. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “**Electronic Delivery**”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute the original form of this Assignment and deliver such form to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, the parties have duly executed this Assignment as of the date first written above.

ASSIGNORS:

AKORN, INC.

By: 
Name: Joseph Bonaccorsi
Title: Executive Vice President, General Counsel and Secretary


ADVANCED VISION RESEARCH, LLC

By: 
Name: Joseph Bonaccorsi
Title: Authorized Signatory

HI-TECH PHARMACAL CO., LLC

By: 
Name: Joseph Bonaccorsi
Title: Authorized Signatory

AKORN ANIMAL HEALTH, LLC

By: 
Name: Joseph Bonaccorsi
Title: Authorized Signatory

CLOVER PHARMACEUTICALS LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

AKORN INTERNATIONAL S.À.R.L.

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory


OAK PHARMACEUTICALS, LLC

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

INSPIRE PHARMACEUTICALS, LLC.

By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

VERSAPHARM LLC


By: 

Name: Joseph Bonaccorsi

Title: Authorized Signatory

ASSIGNEE:

AKORN OPERATING COMPANY LLC

By: 

Name: Joseph Bonaccorsi

Title: Executive Vice President, General Counsel and Secretary

[SIGNATURE PAGE TO TRADEMARK ASSIGNMENT AGREEMENT]

PATENT
REEL: 058107 FRAME: 0644

EXHIBIT A

Trademark Applications

Title	Country	Application No.	Filing Date	Status	Assignor
AKORN	Albania (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	South Korea (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	Bangladesh	202646	10/2/2016	Pending	Akorn, Inc.
AKORN	Botswana	BW/M/2016/00839	9/27/2016	Pending	Akorn, Inc.
AKORN	China (IR)	1336041	9/12/2016	Pending	Akorn, Inc.
AKORN	Ethiopia	FTM/8414/17	3/1/2017	Pending	Akorn, Inc.
AKORN	Indonesia	D002016047722	10/6/2016	Pending	Akorn, Inc.
AKORN	Kuwait	183751	9/25/2016	Pending	Akorn, Inc.
AKORN	Nigeria	F/TM/O/2016/109648	10/4/2016	Pending	Akorn, Inc.
AKORN	Qatar	110397	11/29/2016	Pending	Akorn, Inc.
AKORN	South Africa	2016/26761	9/19/2016	Pending	Akorn, Inc.
AKORN	Sri Lanka	211594	9/27/2016	Pending	Akorn, Inc.
AKORN	Yemen	77345	12/17/2016	Pending	Akorn, Inc.
STERILID	New Zealand	1131346	10/1/2019	Pending	Advanced Vision Research, LLC
THERATEARS	Norway (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, LLC
THERATEARS	Singapore (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, LLC
THERATEARS	South Africa	2014/01774	1/21/2014	Pending	Advanced Vision Research, LLC
THERATEARS	Switzerland (Int'l Reg.)	1197342	1/21/2014	Pending	Advanced Vision Research, LLC
AKORN	India	3537421	9/12/2016	Pending	Akorn, Inc.
AKORN	Nigeria	F/TM/O/2014/18707	6/18/2014	Pending	Akorn Inc.
AK-BETAX	Nigeria	F/TM/O/2014/18595	6/16/2014	Pending	Akorn Inc.
AK-BRIMON	Nigeria	F/TM/O/2014/18626	6/17/2014	Pending	Akorn Inc.
AK-CMC	Nigeria	F/TM/O/2014/18706	6/18/2014	Pending	Akorn Inc.
AK-CROMO	Nigeria	F/TM/O/2014/18630	6/17/2014	Pending	Akorn Inc.
AK-DRAZINE	Nigeria	F/TM/O/2014/18625	6/17/2014	Pending	Akorn Inc.
AK-KETOR	Nigeria	F/TM/O/2014/18622	6/17/2014	Pending	Akorn Inc.
AK-LATAN	Nigeria	F/TM/O/2014/18623	6/17/2014	Pending	Akorn Inc.

Title	Country	Application No.	Filing Date	Status	Assignor
AK-MELLO	Nigeria	F/TM/O/2014/18705	6/18/2014	Pending	Akom Inc.
AK-NAPHALIN	Nigeria	F/TM/O/2014/18704	6/18/2014	Pending	Akom Inc.
AK-NEO-P	Nigeria	F/TM/O/2014/18592	6/16/2014	Pending	Akom Inc.
AK-TEARS	Nigeria	F/TM/O/2014/18593	6/16/2014	Pending	Akom Inc.
AK-TIFEN	Nigeria	F/TM/O/2014/18578	6/16/2014	Pending	Akom Inc.
AKGENTA	Nigeria	F/TM/O/2014/18703	6/18/2014	Pending	Akom Inc.
AKORNAPH	Nigeria	F/TM/O/2015/70291	11/23/2015	Pending	Akom Inc.
AKORNBET	Nigeria	F/TM/O/2015/70285	11/23/2015	Pending	Akom Inc.
AKORNCROM	Nigeria	F/TM/O/2015/70288	11/23/2015	Pending	Akom Inc.
AKORNTARS	Nigeria	F/TM/O/2015/70292	11/23/2015	Pending	Akom Inc.
AKORNTENAC	Nigeria	F/TM/O/2015/70293	11/23/2015	Pending	Akom Inc.
AKORNTIMOL	Nigeria	F/TM/O/2015/70286	11/23/2015	Pending	Akom Inc.
AKORNTIFEN	Nigeria	F/TM/O/2015/70287	11/23/2015	Pending	Akom Inc.
AKORNTRIX	Nigeria	F/TM/O/2015/70290	11/23/2015	Pending	Akom Inc.
AKORN ROLAC	Nigeria	F/TM/O/2015/70294	11/23/2015	Pending	Akom Inc.
DESIGN ONLY	USA	88/581,415	8/16/2019	Pending	Advanced Vision Research, LLC
DETOMISED	USA	88/677,127	11/1/2019	Pending	Akom Animal Health, LLC
MACUTRITION	USA	88/164,134	10/22/2018	Pending	Advanced Vision Research, LLC
PROPOSED	USA	88/677,131	11/1/2019	Pending	Akom Animal Health, LLC
RESTORES + CLEANSSES + NOURISHES and Design	USA	88/072,677	8/9/2018	Pending	Advanced Vision Research, LLC
RESTORES EYES NATURAL BALANCE CLEANSSES EYELIDS AND LASHES NOURISHES EYES TO PROMOTE HEALTHY TEARS and Design	USA	88/070,824	8/9/2018	Pending	Advanced Vision Research, LLC
STERI-OPTICS	USA	87/413,349	4/17/2017	Pending	Hi-Tech Pharmaceutical Co., LLC
THERATEARS EXTRA	USA	88/047,652	7/23/2018	Pending	Advanced Vision Research, LLC

Registered Trademarks

Title	Country	Application No.	Registration No.	Assignor
ADVANCING THE NEW VISION	USA	85114820	3954229	Akorn, Inc.
AK-FLUOR	USA	73652686	1464246	Akorn, Inc.
AKORN	Algeria	164287	99676	Akorn, Inc.
AKORN	Australia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Bosnia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Canada	1792618	TMA987817	Akorn, Inc.
AKORN	Costa Rica	2016-0009676	261950	Akorn, Inc.
AKORN	EUTM (IR)	1336041	1336041	Akorn, Inc.
AKORN	Guatemala	2016009653	229620	Akorn, Inc.
AKORN	Hong Kong	303911643	303911643	Akorn, Inc.
AKORN	India (IR)	1336041	1336041	Akorn, Inc.
AKORN	Iceland (IR)	1336041	1336041	Akorn, Inc.
AKORN	Israel (IR)	292976	292976	Akorn, Inc.
AKORN	Jordan	149710	149710	Akorn, Inc.
AKORN	Kenya	94117	94117	Akorn, Inc.
AKORN	Kosovo	KS/M/2016/1311	21362	Akorn, Inc.
AKORN	Lebanon	N/A	176515	Akorn, Inc.
AKORN	Macedonia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Malaysia	2016067189	2016067189	Akorn, Inc.
AKORN	Montenegro (IR)	1336041	1336041	Akorn, Inc.
AKORN	Nepal	065274	2016/65274	Akorn, Inc.
AKORN	New Zealand (IR)	1063094	1336041	Akorn, Inc.
AKORN	Norway (IR)	1336041	1336041	Akorn, Inc.
AKORN	Panama	253351-01	253351-01	Akorn, Inc.
AKORN	Russia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Saudi Arabia	1437028411	1437028411	Akorn, Inc.
AKORN	Serbia (IR)	1336041	1336041	Akorn, Inc.
AKORN	Singapore (IR)	1336041	1336041	Akorn, Inc.
AKORN	Switzerland (IR)	1336041	1336041	Akorn, Inc.
AKORN	Taiwan	105056232	01856945	Akorn, Inc.
AKORN	Thailand	160108644	191104966	Akorn, Inc.
AKORN	Turkey (IR)	1336041	1336041	Akorn, Inc.
AKORN	UAE	261898	261898	Akorn, Inc.

Title	Country	Application No.	Registration No.	Assignor
AKORN	Ukraine (IR)	1336041	1336041	Akom, Inc.
AKORN	United Kingdom (IR)	1336041	1336041	Akom, Inc.
AKORN	Uruguay	441,150	441,150	Akom, Inc.
AKORN	USA	77589830	3,774,019	Akom, Inc.
AKORN	USA	86937435	5,076,962	Akom, Inc.
AKTEN	Israel	291476	291476	Akom, Inc.
AKTEN	USA	77012922	3,631,872	Akom, Inc.
AKWA TEARS	USA	75829828	2,429,583	Akom, Inc.
ALLERGY BUSTER	Canada	1449252	TMA787366	Hi-Tech Pharmacal Co., LLC
ALLERGY BUSTER & DESIGN	EU	008506347	008506347	Hi-Tech Pharmacal Co., LLC
AMICAR	USA	72124870	729,648	Clover Pharmaceuticals LLC
ANASED	Canada	0878555	TMA526130	Akom Animal Health, LLC
ANASED	USA	73815445	1,589,685	Akom Animal Health, LLC
BETIMOL	International Register	728498 A	728498 A	Akom International S.A.R.L.
BETIMOL	USA	74628335	1,961,729	Akom International S.A.R.L
BETIMOL	USA	79128616	4,442,019 (IR No. 728489A)	Akom International S.A.R.L
BUTORPHIC	USA	77492827	3,648,627	Akom Animal Health, LLC
CAPASTAT	Canada	0294218	TMA147966	Akom, Inc.
CAPASTAT	USA	72221381	808,363	Akom, Inc.
CHOICE DM	Canada	0821371	TMA535139	Hi-Tech Pharmacal Co., LLC
CONTROL THE UNCONTROLLABLE	USA	85961915	4,732,151	Oak Pharmaceuticals, LLC
DIABETIC TUSSIN	USA	74389373	1,861,344	Hi-Tech Pharmacal Co., LLC
DIADERM	USA	86025876	4,573,615	Hi-Tech Pharmacal Co., LLC
EYE RX DIRECT (design)	USA	86773391	5,296,978	Akom, Inc.

Title	Country	Application No.	Registration No.	Assignor
FAST AND FIERCE RELIEF	USA	87007235	5,355,854	Hi-Tech Pharmaceutical Co., LLC
AKORN PHARMACAL, INC.	US State/Louisiana	N/A	658495	Hi-Tech Pharmaceutical Co., LLC
FLURESS	USA	72203731	789,323	Akorn, Inc.
GENT-AK	USA	73652684	1,464,244	Akorn, Inc.
GROUNDEN IN SCIENCE. PROVEN IN PRACTICE	USA	85961910	4,748,523	Oak Pharmaceuticals, LLC
HEADACHE BUSTER	Canada	1449250	TMA787365	Hi-Tech Pharmaceutical Co., LLC
IC-GREEN	Canada	0855183	TMA531645	Akorn, Inc.
IC-GREEN	Denmark	VA 003089 1997	VR 199703234	Akorn, Inc.
IC-GREEN	France	97/684025	97/684025	Akorn, Inc.
IC-GREEN	Germany	39729824.2	39729824	Akorn, Inc.
IC-GREEN	Italy	362017000074996	362017000074996	Akorn, Inc.
IC-GREEN	Switzerland	4701/1997	447511	Akorn, Inc.
IC-GREEN	USA	75315149	2,189,196	Akorn, Inc.
INAPSINE	USA	72190096	783,911	Akorn, Inc.
INDIGO CARMINE	USA	75825569	2,389,845	Akorn, Inc.
HYCILIA	Argentina	3011174	2442900	Inspire Pharmaceuticals, LLC
INSPIRE	USA	76308782	2,578,523	Inspire Pharmaceuticals, LLC
INSPIRE (& design)	USA	76309035	2,578,526	Inspire Pharmaceuticals, LLC
JEFFREY P. GILBARD, MD	USA	85121025	4,556,180	Advanced Vision Research, LLC
MAGINEX	Canada	1083318	TMA641833	Hi-Tech Pharmaceutical Co., LLC
MAGINEX	USA	76052135	2,541,622	Hi-Tech Pharmaceutical Co., LLC
MAG-OX 400	USA	75576028	2,633,768	Hi-Tech Pharmaceutical Co., LLC
MASTER OF MAGNESIUM	USA	87007233	5,355,853	Hi-Tech Pharmaceutical Co., LLC
MULTI-BETIC	USA	86210334	4,613,666	Hi-Tech Pharmaceutical Co., LLC

Title	Country	Application No.	Registration No.	Assignor
MYOCHRYSLINE	USA	76178246	2,509,820	Akorn, Inc.
MYORISAN	Canada	1809727	TMA1031869	VersaPharm LLC
MYORISAN	USA	85071559	4,199,023	VersaPharm LLC
NEMBUTAL	Canada	0181445	UCA17215	Oak Pharmaceuticals, LLC
NEMBUTAL	USA	71308321	285,003	Oak Pharmaceuticals, LLC
OSMO-CORRECTION	USA	85967253	4,837,201	Advanced Vision Research, LLC
PAREMYD	USA	75839701	2,775,998	Akorn, Inc.
PHARMACEUTICAL GRADE (& design)	USA	78329276	3,272,765	Hi-Tech Pharmaceutical Co., LLC
RESTORES EYES NATURAL BALANCE	USA	85967251	4,846,473	Advanced Vision Research, LLC
SINUS BUSTER	Canada	1378181	TMA733034	Hi-Tech Pharmaceutical Co., LLC
SINUS BUSTER	USA	78862364	3,194,160	Hi-Tech Pharmaceutical Co., LLC
SINUS BUSTER ALL NATURAL NASAL SPRAY	USA	78850704	3,503,088	Hi-Tech Pharmaceutical Co., LLC
SINUS GENIE	Canada	1378171	TMA732672	Hi-Tech Pharmaceutical Co., LLC
STERILID	Australia	1064550	1064550	Advanced Vision Research, LLC
STERILID	EU	004549721	004549721	Advanced Vision Research, LLC
STERILID	India	1376561	1376561	Advanced Vision Research, LLC
STERILID	Mexico	731418	907,931	Advanced Vision Research, LLC
STERILID	USA	78459733	3,140,041	Advanced Vision Research, LLC
T TAYLOR PHARMACEUTICALS AN AKORN COMPANY	USA	75572570	2,340,300	Akorn, Inc.
TEARS RENEWED	USA	75829829	2,429,584	Akorn, Inc.
THERA LID	Canada	1387723	TMA766,079	Advanced Vision Research, LLC
THERA TEARS	EU	002996155	002996155	Advanced Vision Research, LLC

Title	Country	Application No.	Registration No.	Assignor
THERA TEARS	Mexico	731417	902036	Advanced Vision Research, LLC
THERA TEARS	USA	88457133	5,943,133	Advanced Vision Research, LLC
THERA TEARS	USA	74615598	2,041,112	Advanced Vision Research, LLC
THERAPY FOR YOUR EYES	USA	86260607	4,843,058	Advanced Vision Research, LLC
THERATEARS EXTRA	USA	87049747	5,586,699	Advanced Vision Research, LLC
THERATEARS	Australia	730182	730182	Advanced Vision Research, LLC
THERATEARS	Canada	1085366	TMA573256	Advanced Vision Research, LLC
THERATEARS	Canada	1153395	TMA641310	Advanced Vision Research, LLC
THERATEARS	EU	002153476	002153476	Advanced Vision Research, LLC
THERATEARS	Guatemala	2014000962	201476	Advanced Vision Research, LLC
THERATEARS	India	1376560	1376560	Advanced Vision Research, LLC
THERATEARS	International Register	1197342	1197342	Advanced Vision Research, LLC
THERATEARS	Lebanon	N/A	155229	Advanced Vision Research, LLC
THERATEARS	New Zealand	274324	274324	Advanced Vision Research, LLC
THERATEARS	USA	76427523	2,770,188	Advanced Vision Research, LLC
THERATEARS STERILID	USA	78459728	3,181,614	Advanced Vision Research, LLC
TOLAZINE	USA	76548343	2,905,937	Akorn Animal Health, LLC
TYPE YOU	Canada	1728450	TMA1040395	Akorn, Inc.
TYPE YOU	USA	86631044	5,291,486	Akorn, Inc.
TYPE YOU DIABETIC CARE	Canada	1776093	TMA1047727	Akorn, Inc.
TYPE YOU DIABETIC CARE	USA	86966811	5,297,364	Akorn, Inc.

Title	Country	Application No.	Registration No.	Assignor
URO-MAG	USA	72450878	974,841	Hi-Tech Pharmaceutical Co., LLC
MYORISAN	Mexico	1144174	1217500	VersaPharm LLC
VERSAPHARM INCORPORATED	USA	76269614	2,588,146	VersaPharm LLC
VERSAPHARM INCORPORATED X	USA	76269637	2,685,550	VersaPharm LLC
AKORN PHARM, INC.	US State/Louisiana	N/A	658517	VersaPharm LLC
VETAKET	USA	74266573	1,803,032	Akorn Animal Health, LLC
VO SOL	USA	72081126	696,678	Hi-Tech Pharmaceutical Co., LLC
YOBINE	USA	73815446	1,587,410	Akorn Animal Health, LLC
ZOSTRIX	USA	78660833	3,106,587	Hi-Tech Pharmaceutical Co., LLC
ZOSTRIX	USA	73576274	1,423,561	Hi-Tech Pharmaceutical Co., LLC
THERATEARS	Kuwait	N/A	130439	Advanced Vision Research, LLC

EXHIBIT 2

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6871943

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
AKORN OPERATING COMPANY LLC	08/02/2021
RECEIVING PARTY DATA	
Name:	MEDTECH PRODUCTS INC.
Street Address:	660 WHITE PLAINS ROAD
Internal Address:	SUITE 250
City:	TARRYTOWN
State/Country:	NEW YORK
Postal Code:	10591
PROPERTY NUMBERS Total: 15	
Property Type	Number
Application Number:	16997148
Application Number:	17211952
Patent Number:	8231912
Application Number:	14722252
Patent Number:	8449928
Patent Number:	8932653
Patent Number:	9050288
Patent Number:	8900643
Patent Number:	9301988
Patent Number:	8535736
Application Number:	62955249
Application Number:	62991743
Application Number:	13961453
Application Number:	14617404
Application Number:	15674791
CORRESPONDENCE DATA	
Fax Number:	(312)207-6400
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.	

PATENT

Phone: 2125494195
Email: gbenoy@reedsmith.com
Correspondent Name: PETER A. EMMI
Address Line 1: 599 LEXINGTON AVENUE, 22ND FLOOR
Address Line 2: REED SMITH LLP
Address Line 4: NEW YORK, NEW YORK 10022

ATTORNEY DOCKET NUMBER: 330225.00028

NAME OF SUBMITTER: GWEN M. BENOY

SIGNATURE: /Gwen M. Benoy/

DATE SIGNED: 08/18/2021

Total Attachments: 46

source=IP_Assignment#page1.tif
source=IP_Assignment#page2.tif
source=IP_Assignment#page3.tif
source=IP_Assignment#page4.tif
source=IP_Assignment#page5.tif
source=IP_Assignment#page6.tif
source=IP_Assignment#page7.tif
source=IP_Assignment#page8.tif
source=IP_Assignment#page9.tif
source=IP_Assignment#page10.tif
source=IP_Assignment#page11.tif
source=IP_Assignment#page12.tif
source=IP_Assignment#page13.tif
source=IP_Assignment#page14.tif
source=IP_Assignment#page15.tif
source=IP_Assignment#page16.tif
source=IP_Assignment#page17.tif
source=IP_Assignment#page18.tif
source=IP_Assignment#page19.tif
source=IP_Assignment#page20.tif
source=IP_Assignment#page21.tif
source=IP_Assignment#page22.tif
source=IP_Assignment#page23.tif
source=IP_Assignment#page24.tif
source=IP_Assignment#page25.tif
source=IP_Assignment#page26.tif
source=IP_Assignment#page27.tif
source=IP_Assignment#page28.tif
source=IP_Assignment#page29.tif
source=IP_Assignment#page30.tif
source=IP_Assignment#page31.tif
source=IP_Assignment#page32.tif
source=IP_Assignment#page33.tif
source=IP_Assignment#page34.tif
source=IP_Assignment#page35.tif

source=IP_Assignment#page36.tif
source=IP_Assignment#page37.tif
source=IP_Assignment#page38.tif
source=IP_Assignment#page39.tif
source=IP_Assignment#page40.tif
source=IP_Assignment#page41.tif
source=IP_Assignment#page42.tif
source=IP_Assignment#page43.tif
source=IP_Assignment#page44.tif
source=IP_Assignment#page45.tif
source=IP_Assignment#page46.tif